Muscular Atrophy clinical trials

Explore recruiting muscular atrophy clinical trials.

Recruiting muscular atrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Muscular Atrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Poland, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101

Belgium, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials

Netherlands, Belgium, France, Denmark, Spain, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)

Italy, Poland, Spain, Germany, Belgium, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered via the ThecaFlex DRx™ System (PIERRE-PK)

Poland, France, Spain, Germany, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen - ONWARD

Italy, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Muscular Atrophy trials by city

Muscular Atrophy in Toronto Muscular Atrophy in Vancouver Muscular Atrophy in Montreal Muscular Atrophy in Calgary Muscular Atrophy in Edmonton Muscular Atrophy in Ottawa Muscular Atrophy in Winnipeg Muscular Atrophy in Quebec City Muscular Atrophy in Hamilton Muscular Atrophy in Kitchener Muscular Atrophy in London Muscular Atrophy in Halifax Muscular Atrophy in New York Muscular Atrophy in Los Angeles Muscular Atrophy in Chicago Muscular Atrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease